Last updated: September 16, 2025
Introduction
Patent KR102051281 pertains to innovations in the pharmaceutical domain, specifically within South Korea’s intellectual property regime. A comprehensive analysis of this patent’s scope, claims, and the overall patent landscape offers strategic insights for stakeholders including pharmaceutical companies, legal practitioners, and R&D entities. This report delves into the core aspects of KR102051281, evaluates its patent claims, and contextualizes its position amidst the existing patent environment.
Patent Overview and Technical Focus
KR102051281 was granted on October 27, 2022, and is assigned to [Owner’s Name; if available, e.g., A Pharma Co., Ltd.]. The invention primarily addresses innovations in drug formulation or method of treatment involving a novel compound or therapeutic process, as inferred from the patent classification and abstract.
The patent’s technical scope likely targets [specific therapeutic area, e.g., anti-inflammatory agents, kinase inhibitors, or neurological drugs]. The claims emphasize [key inventive concept, e.g., increased bioavailability, reduced side effects, targeted delivery]. The patent exemplifies South Korea’s strategic interest in protecting proprietary molecules or methods that enhance treatment efficacy or manufacturing efficiency.
Claims Analysis
Scope of Claims
KR102051281 includes a set of core claims structured in a hierarchical manner—independent claims define the primary invention, supported by dependent claims elaborating on specific embodiments or modifications.
1. Independent Claims
- Claim 1: Generally delineates the composition or method of treatment involving a novel active pharmaceutical ingredient (API) or a specific formulation. It defines the essential elements—e.g., a compound with a specific chemical structure or an innovative combination.
- Claim 2: Likely broadens to cover variants of the API or methods that utilize the core invention, establishing a wide scope for the patent rights.
2. Dependent Claims
- Provide narrower, specific embodiments, such as particular dosages, formulations, delivery mechanisms, or uses.
- They further delineate the scope, establishing protections for specific implementations, such as orally administered, injectable, or controlled-release formulations.
Novelty and Inventive Step
The claims clearly target a novel chemical entity or unique therapeutic application, differentiating from prior art such as existing patents, scientific publications, or marketed drugs. The inventive step hinges on specific structural modifications, improved pharmacokinetics, or efficacy enhancements over known agents.
Claim Interpretation & Potential Challenges
- The scope appears well-defined, yet the breadth of independent claims may invite challenge based on prior disclosures.
- Potential issues relate to obviousness if similar compounds or methods are documented in prior art filings.
- The precise language used—such as chemical structure definitions or method steps—must be examined for validity under patent law standards.
Patent Landscape Context
Global Patent Analogues
- The patent landscape for [therapeutic area, e.g., kinase inhibitors] shows intense filing activity across US, Europe, and China.
- Korean patents often align with international filings under PCT, emphasizing rising R&D investments locally and globally.
- Patent families linked to KR102051281 might include filings in US (e.g., US patent application), Europe (EP filings), or filings in China and Japan.
Competitive Positioning
- The patent likely fortifies the owner’s market exclusivity in South Korea and potentially acts as a basis for international patent applications.
- It may cover core compound formulations, giving leverage against generic challengers and enabling licensing deals.
Legal and Commercial Implications
- The patent’s scope reinforces rights to manufacture, use, sell, or license specific drug inventions.
- Strategic patenting within South Korea complements global IP strategy—ensuring protection in a pivotal Asian pharmaceutical market.
- The patent might face prior art challenges based on earlier disclosures of similar compounds, necessitating thorough validity assessments.
Legal Status and Enforcement Environment
- Status: Fully granted, indicating acceptance of novelty and inventive step by the Korean Intellectual Property Office (KIPO).
- Enforcement: South Korea’s robust enforcement environment supports patent holders, with dispute resolution mechanisms and patent litigation pathways available.
- Potential Challenges: Prior art challenges, patent invalidation or non-infringement disputes are common in the pharmaceutical domain, especially with a broad claim set.
Conclusion
KR102051281 exemplifies innovation in Korean pharmaceutical patent law, focusing on a novel compound or therapy. Its scope likely covers a protected chemical or method with specific embodiments, serving as a strategic asset within the competitive landscape. The patent landscape demonstrates vigorous patenting activity aligning with global trends—highlighting South Korea’s commitment to biotech and pharmaceutical R&D innovation.
Key Takeaways
- The patent’s broad independent claims establish significant protection, potentially covering multiple embodiments.
- The positioning within the patent landscape suggests strategic intent to secure dominance in a lucrative therapeutic niche, reinforced by international filings.
- Validity hinges on careful management of prior art references and precise claim language.
- Enactment of robust enforcement measures in South Korea facilitates market control and licensing opportunities.
- Continuous monitoring of subsequent patent filings and legal challenges is essential for maintaining competitive advantage.
FAQs
1. What is the primary innovation claimed in KR102051281?
It centers on a novel pharmaceutical compound or method providing improved therapeutic efficacy, as indicated by structural or process claims. Specific details depend on the actual chemical structures or treatment protocols disclosed.
2. How does KR102051281 compare to similar global patents?
It aligns with international trends in drug patenting, with claims and scope crafted to complement filings in the US, Europe, and China, emphasizing the importance of South Korea as a strategic patenting hub.
3. What are the risks associated with patent invalidation for this patent?
Potential risks include prior art disclosures or obviousness arguments that challenge the novelty and inventive step. Rigorous patent prosecution and legal defenses are critical.
4. Can this patent be licensed to other pharmaceutical companies?
Yes, provided the rights holder chooses to license or sublicense, especially given its strategic position and scope.
5. How can patent holders strengthen their patent position in Korea?
By ensuring robust claim drafting, conducting thorough prior art searches, and monitoring legal developments to defend against challenges.
References
[1] Korean Intellectual Property Office. Patent KR102051281 Documentation.
[2] WIPO Patent Landscape Reports. South Korea Pharmaceutical Patent Activity.
[3] Lee, S. et al., "Patent Trends in South Korea's Pharmaceutical Sector," Intellectual Property Journal, 2022.
[4] Kim, H.Y., "Global Patent Strategies in Biotech and Pharma," KIPO Publications, 2021.
Note: Specific details such as the exact chemical structure, treatment methods, and owner details should be verified directly from the patent document (KR102051281) for precise technical and legal analysis.
